Semaglutide treatments offer numerous benefits when used as part of a comprehensive weight loss management strategy with clinical trials showcasing its effectiveness
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists demonstrate consistent risk reductions for mortality, myocardial infarction, stroke, heart failure, and renal outcomes, irrespective of their effects on glycemia
This approach mirrors how longevity-focused clinicians use other interventions, prioritizing a sustained, low-amplitude signal over a short, high-amplitude intervention
Several studies have investigated whether weight loss medications like Wegovy and Mounjaro can improve sleep apnoea, although evidence is mixed
glutathione is a primary fuel for liver health
Balci A, Koksal O, Kose A, et